不同生物膜形成能力耐碳青霉烯类鲍曼不动杆菌的Bap基因分析

中国药物评价 ›› 2022, Vol. 39 ›› Issue (2): 148-152.

不同生物膜形成能力耐碳青霉烯类鲍曼不动杆菌的Bap基因分析

方甜甜，任宝军²，宋沧桑¹，唐树荣²，李兴德¹，杨焕芝¹，刘德华^2*

1.昆明市第一人民医院药学部，云南昆明 650031； 2.昆明市第一人民医院检验科，云南昆明 650031

收稿日期:2021-04-20 修回日期:2021-12-20 出版日期:2022-04-28 发布日期:2022-04-28
基金资助:
昆明市科技局项目(No. 2019KJJH073)；云南省教育厅科学研究基金项目(No. 2019J1295)；昆明市卫生科技人才培养项目[项2020-SW(后备)-36]

Analysis of Bap Gene of Carbapenem-resistant Acinetobacter Baumannii with Different Biofilm forming Ability

1.Department of Pharmacy, Kunming First People′s Hospital, Yunnan Kunming 650031, China; 2.Laboratory Department, Kunming First People′s Hospital, Yunnan Kunming 650031, China

Received:2021-04-20 Revised:2021-12-20 Online:2022-04-28 Published:2022-04-28
Contact: liu dehua E-mail:2539415043@qq.com

摘要/Abstract

摘要：

目的：对不同生物膜形成能力耐碳青霉烯类鲍曼不动杆菌(CRAB)的bap耐药基因进行分析。方法：本研究纳入某院2019年2月至2020年9月临床分离的36株CRAB，采用结晶紫半定量法测定CRAB的生物膜形成能力，采用PCR法检测其中10株菌株的bap耐药基因。结果：10株临床分离的CRAB中，bapⅠ和bapⅣ的检出率均为100%，bapⅢ的检出率均为0%。bapⅡ的总检出率为70%，其中生物膜形成能力弱阳性组的bapⅡ检出率为60%，生物膜形成能力阳性组的bapⅡ检出率为80%。从耐药率看，10株细菌中，头孢唑啉、厄它培南、氨曲南和阿莫西林/棒酸的耐药率均为100%，替加环素的耐药率均为0%(均为敏感)。bapⅡ检出组的妥布霉素、头孢吡肟、头孢噻肟、头孢曲松、亚胺培南、美罗培南、头孢哌酮/舒巴坦、环丙沙星、左氧氟沙星、庆大霉素和哌拉西林/他唑巴坦的耐药率均高于bapⅡ未检出组。结论：CRAB的生物膜形成能力可能随着BAPⅡ检出率的增高而增强。CRAB的耐药性除与耐药基因有关，还可能与bap基因多态性有关。

关键词: 生物膜, 耐碳青霉烯类鲍曼不动杆菌(CRAB), Bap基因

Abstract:

Objective：The bap resistance genes of carbapenem-resistant acinetobacter baumannii with different biofilm forming abilities were analyzed. Methods: 36 strains of carbapenem-resistant acinetobacter baumannii that were clinically isolated from a hospital between February 2019 and September 2020 were included. The biofilm formation ability of carbapenem-resistant acinetobacter baumannii was determined by semi-quantitative crystal violet method, and bap gene of 10 of them was detected by PCR. Results: In 10 clinically isolated CRAB strains, the detection rates of bapⅠ， bap Ⅳ， bap Ⅲ and bap Ⅱ were 100%，100%, 0% and 70% respectively. The drug resistance rates of cefazoline, etapenem, amoxicillin and amoxicillin/roguic acid were all 100%, and the drug resistance rates of tigecycline were all 0%. The detection rate of bap Ⅱ was 60% in the group with weakly positive biofilm formation ability, and 80% with positive biofilm formation ability. The drug resistance rates in bap Ⅱ detection group were all higher than bap Ⅱ no detection group. Conclusion: The biofilm forming ability of CRAB may increase with the detection rate of bap Ⅱ. The resistance of CRAB is related not only to drug-resistant genes, but also to bap gene polymorphism.

Key words: Biofilm, Carbapenem-resistant Acinetobacter baumannii(CRAB), Bap gene

中图分类号:

R978
Q734

方甜甜, 任宝军 , 宋沧桑, 唐树荣, 李兴德, 杨焕芝, 刘德华.

不同生物膜形成能力耐碳青霉烯类鲍曼不动杆菌的Bap基因分析 [J]. 中国药物评价, 2022, 39(2): 148-152.

FANG Tian-tian, REN Bao-jun, SONG Cang-sang, TANG Shu-rong, LI Xing-de, YANG Huan-zhi, LIU De-hua.

Analysis of Bap Gene of Carbapenem-resistant Acinetobacter Baumannii with Different Biofilm forming Ability [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2022, 39(2): 148-152.

参考文献

[1] Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases[J]. Nat Rev Microbiol，2004，2(2)：95-108.

[2] Vatan A, Saltoglu N, Yemisen M, et al. Association between biofilm and multi/extensive drug resistance in diabetic foot infection[J]. Int J Clin Pract，2018，72(3)：1-7.

[3] Babapour E, Haddadi A, Mirnejad R, et al. Biofilm formation in clinical isolates of nosocomial Acinetobacter baumannii and its relationship with multidrug resistance[J]. Asian Pac J Trop Biomed，2016，6(6)：528-533.

[4] Tomaras AP, Flagler MJ, Dorsey CW, et al. Characterization of a two component regulatory system from Acinetobacter baumannii that controls biofilm formation and cellular morphology [J]. Microbiology，2008，154 (11)：3398-3409.

[5] 杨均均，黄文祥，史芳静，等. 耐碳青霉烯鲍曼不动杆菌流行特征及耐药基因分析[J].中国抗生素杂志，2012，37(5)：343-347.

[6] 戚丽华. 鲍曼不动杆菌耐药特性及其与生物膜的相关性研究[D].中国人民解放军军事医学科学院，2016.

[7] Fattahian Y, Rasooli I, Gargari SLM, et al. Protection against Acinetobacter baumannii infection via its functional deprivation of biofilm associated protein (Bap)[J]. Microb Pathog，2011, 51(6)：402-406.

[8] Murray BLL. Investigating the role of antibodies against the biofilm associated protein (BAP) of Acinetobacter baumannii[D].University of Manitoba，2011.

[9] Goh HS, Beatson SA, Totsika M, et al. Molecular analysis of the Acinetobacter baumannii biofilm-associated protein[J]. Appl Environ Microbiol，2013，79(21): 6535-6543.

[10] 尹珍，黄文祥，杨均均，等.耐碳青霉烯类鲍曼不动杆菌流行克隆株生物被膜形成能力分析[J].中国感染与化疗杂志，2018，18(2): 184-189.

[11] Loehfelm, TW, Luke NR, Campagnari AA. Identification and characterization of an Acinetobacter baumannii biofilm-associated protein[J]. Journal of bacteriology, 2008，190(3)：1036-1044.

[12] Di Luca M, Maccari G，Nifosì R. Treatment of microbial biofilms in the post- antibiotic era: prophylactic and therapeutic use of antimicrobial peptides and their design by bioinformatics tools.[J]. Pathogens and disease, 2014，70(3)：257-270

[13] Goh HM，Beatson SA，Totsika M，et al.Molecular analysis of the Acinetobacter baumannii biofilm-associated protein[J]. Applied and environmental microbiology，2013，79(21)：6535-6543

[14] De Gregorio E，Del Franco M，Martinucci M，et al. Biofilm-associated proteins: news from Acinetobacter[J]. BMC Genomics, 2015，16(1)：933

[15] 刘鑫喆，滑明溪，王慧珠，等.基于全基因组序列的耐碳青霉烯鲍曼不动杆菌的耐药与毒力研究[J].中华实验和临床感染病杂志，2020，14(5)：367-373.